A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Eravacycline (Primary) ; Meropenem
  • Indications Appendicitis; Intra-abdominal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNITE4
  • Sponsors Tetraphase Pharmaceuticals
  • Most Recent Events

    • 11 Sep 2017 Status changed from active, no longer recruiting to completed according to a Tetraphase Pharmaceuticals media release.
    • 25 Jul 2017 Primary endpoint has been met. (Number of Participants with a Favorable Clinical Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population), according to a Tetraphase Pharmaceuticals media release.
    • 25 Jul 2017 According to a Tetraphase Pharmaceuticals media release, detailed results from this trial will be presented at a future scientific meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top